Literature DB >> 19799468

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences.

Björn Wettermark1, Brian Godman, Bengt Jacobsson, Flora M Haaijer-Ruskamp.   

Abstract

It is a challenge to improve public health within limited resources. Pharmaceutical policy making is a greater challenge due to conflicting interests between key stakeholder groups. This paper reviews current and future strategies to help improve the quality and efficiency of care, with special emphasis on demand-side controls for pharmaceutical prescribing. A large number of different educational, organizational, financial and regulatory strategies have been applied in pharmaceutical policy making. However, the effectiveness of most strategies has not been thoroughly evaluated and there is evidence that the behaviour of healthcare professionals is difficult to influence with traditional methods. During the last decades, new modes of governing and new governing constellations have also appeared in healthcare. However, relationships between those who regulate and those regulated are often unclear. New approaches have recently been introduced, including extensive dissemination strategies for guidelines and extensive quality assessment programmes where physicians' performances are measured against agreed standards or against each other. The main components of these 'soft regulations' are standardization, monitoring and agenda setting. However, the impact of these new modes on health provision and overall costs is often unknown, and the increased focus on monitoring may result in a higher conformity and uniformity that may not always benefit all key stakeholders. Alongside this, a substantial growth of auditing associations controlling a diminishing minority of people actually performing the tasks may be costly and counter-productive. As a result, new effective strategies are urgently needed to help maintain comprehensive healthcare without prohibitively raising taxes or insurance premiums. This is especially important where countries are faced with extreme financial problems. Healthcare researchers may benefit from researching other areas of society. However, any potential strategies initiated must be adequately researched, debated and evaluated to enhance implementation. We hope this opinion paper is the first step in the process to develop and implement new demand-side initiatives building on existing 'soft regulations'.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19799468     DOI: 10.1007/bf03256147

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  20 in total

Review 1.  Impact of European pharmaceutical price regulation on generic price competition: a review.

Authors:  Jaume Puig-Junoy
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  The influence of hospital drug formulary policies on the prescribing patterns of proton pump inhibitors in primary care.

Authors:  Michael Due Larsen; Mette Schou; Anja Sparre Kristiansen; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2014-04-27       Impact factor: 2.953

Review 3.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

4.  The intriguing future of pharmacoepidemiology.

Authors:  Björn Wettermark
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

5.  Policies to enhance prescribing efficiency in europe: findings and future implications.

Authors:  Brian Godman; William Shrank; Morten Andersen; Christian Berg; Iain Bishop; Thomas Burkhardt; Kristina Garuoliene; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Julie Lonsdale; Rickard E Malmström; Jaana E Martikainen; Vita Samaluk; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; Lesley Tilson; F Cankat Tulunay; Vera Vlahović-Palčevski; Kamila Wendykowska; Bjorn Wettermark; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2011-01-07       Impact factor: 5.810

6.  The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.

Authors:  Amanj Baker; Li-Chia Chen; Rachel A Elliott; Brian Godman
Journal:  BMC Health Serv Res       Date:  2015-09-10       Impact factor: 2.655

Review 7.  Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.

Authors:  Brian Godman; Bjorn Wettermark; Menno van Woerkom; Jessica Fraeyman; Samantha Alvarez-Madrazo; Christian Berg; Iain Bishop; Anna Bucsics; Stephen Campbell; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Harald Herholz; Marija Kalaba; Ott Laius; Jutta Piessnegger; Catherine Sermet; Ulrich Schwabe; Vera V Vlahović-Palčevski; Vanda Markovic-Pekovic; Luka Vončina; Kamila Malinowska; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2014-06-17       Impact factor: 5.810

Review 8.  Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.

Authors:  Brian Godman; Rickard E Malmström; Eduardo Diogene; Sisira Jayathissa; Stuart McTaggart; Thomas Cars; Samantha Alvarez-Madrazo; Christoph Baumgärtel; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Irene Eriksson; Alexander Finlayson; Jurij Fürst; Kristina Garuoliene; Iñaki Gutiérrez-Ibarluzea; Krystyna Hviding; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Kamila Malinowska; Hanne B Pedersen; Vanda Markovic-Pekovic; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Susan Spillane; Dominik Tomek; Luka Vončina; Vera Vlahović-Palčevski; Janet Wale; Magdalena Wladysiuk; Menno van Woerkom; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2014-06-10       Impact factor: 5.810

9.  Different initiatives across Europe to enhance losartan utilization post generics: impact and implications.

Authors:  James C Moon; Brian Godman; Max Petzold; Samantha Alvarez-Madrazo; Kathleen Bennett; Iain Bishop; Anna Bucsics; Ulrik Hesse; Andrew Martin; Steven Simoens; Corinne Zara; Rickard E Malmström
Journal:  Front Pharmacol       Date:  2014-10-08       Impact factor: 5.810

10.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.